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CHAPTER I 
 
INTRODUCTION 
Diabetes mellitus 
Diabetes mellitus is a collection of chronic diseases that occurs when the pancreas 
cannot efficiently produce an adequate amount of insulin or when the body does not 
effectively use the insulin produced from the pancreas. Insulin is produced by islet cells 
in the pancreas and has profound effects on metabolism. Insulin is required for the uptake 
of glucose from the blood in liver, muscle, and fat cells. When insulin regulation is 
disrupted, cells fail to acquire glucose and the body begins to use fat as an energy source, 
resulting in potentially severe anabolic effects on the body. Diabetes mellitus takes on 
three main forms, all of which are characterized by high blood glucose.  Type 1 diabetes 
is an autoimmunie disease where the body eventually no longer makes insulin.  Type 2 
diabetes (T2D), unlike type 1, is a result of insulin resistance.  Gestational diabetes 
occurs during pregnancy in mothers that do not initially present with type 2 diabetes.  The 
work presented here focuses on the most common form of diabetes melltus:  T2D.  
Epidemiology of Type 2 Diabetes 
 As of 2011, 346 million people worldwide have diabetes with over 90% of all 
diabetes cases being T2D (WHO, 2011). This is an alarming estimate particularly 
because in 2000 it was predicted that 366 million people will have diabetes in the year 
2030, just 20 million more than the 2011 estimate (Figure 1.1) (Wild et al., 2004).  There 
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has been a rapid increase of T2D in developing countries, as more individuals are 
adopting high fat diets and decreased physical inactivity (Figure 1.1) (Hossain et al., 
2007). By 2030, the prevalence of T2D in the Middle East, India, Southeast Asia, and 
Sub-Saharan African is expected to increase by >150% (Figure 1.1) (Hossain et al., 
2007). The interaction with T2D prevalence and poverty is complex. Low income 
countries tend to have lower rates of T2D compared to middle income countries (Figure 
1.2).  Yet in developed countries, impoverished communities suffer from T2D and have 
increased T2D risk factors compared to more affluent communities. It is suspected that 
this is due to the low cost and overconsumption high fat foods leading to increased 
obesity rates, a T2D risk factor (Hossain et al., 2007).  
Type 2 diabetes also affects the industrialized and developed world. In the United 
States 25.8 million people have diabetes, which accounts for 8.3% of the total U.S. 
population (ADA, 2011).  Consistent with global estimates, T2D accounts for 93% of all 
diabetes cases in the U.S. In 2007, diabetes was the underlying cause or contributing 
factor to about 230,000 deaths in the U.S. (ADA, 2011).  It is predicted that the 
prevalence and consequently the mortality rate of T2D or related complications will 
double if not triple by the year 2030 (Figure 1.1) (ADA, 2011; Hossain et al., 2007).  
The distribution of individuals with T2D is disproportionate across race/ethnicity. 
In the United States, the burden of diabetes is higher in minority populations compared to 
European descent populations (Mokdad et al., 2000). National survey data report 8.4% of 
Asian Americans, 11.8% of Hispanics, 12.6% of non-Hispanic blacks, and 16.1% of 
American Indians are diagnosed with diabetes at rates higher than non-Hispanic whites 
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(7.2%, a European descent population) (Centers for Disease Control and Prevention, 
2011).  
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Figure 1.1 Prevalence of T2D in 2000 and Projections for 2030, with Projected Percent Changes. Numbers 
indicate the proportion (%) of the population with T2D. Modified from (Hossain et al., 2007). 
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Figure 1.2 Global prevalence of diabetes in adults ages 25+ years, by WHO Region 
and World Bank income groups, 2008 (WHO, 2011). Abbreviations: AFR= African 
Region, AMR= Region of the Americas, EMR= Eastern Mediterranean Region, EUR= 
European Region, SEAR= South-East Asia Region, WPR= Western Pacific Region).  
 
Risk Factors of Type 2 Diabetes 
  There are several risk factors that might explain the recent increase of T2D 
incidence. Metabolic diseases, such as T2D have a complex disease etiology and are 
likely caused by a combination of several environmental and genetic risk factors. 
Increased body mass index (BMI), as a result of poor diet and a sedentary lifestyle, is the 
major risk factor for T2D (Mozaffarian et al., 2009).  Under the clinical definition of 
obesity (BMI >30),  85% of T2D cases are obese (National Institute of Diabetes and 
Kidney Disease, 2007).   Beta cells in obese individuals become insulin resistant leading 
to increased blood glucose (Schinner et al., 2005). Obese individuals have higher lipid 
levels in the blood, resulting in an accumulation of triglycerides in muscle cells, therby 
reducing glucose uptake regardless of insulin levels (Schinner et al., 2005; Morino et al., 
2006). Insulin insensitivity as a result of obesity is a clinical characteristic of T2D. To a 
lesser extent, risk factors such as smoking, stress, and lack of sleep are also associated 
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with T2D.  All of these risk factors, including obesity, are modifiable (Mozaffarian et al., 
2009). 
Increased age, gender, and family history are additional risk factors of T2D that 
are not modifiable. In the U.S., 26.9% of all adults over the age of 65 have diagnosed 
diabetes compared to 11.3% under 65 (Centers for Disease Control and Prevention, 
2011).  Being female has been previously associated with obesity and increased T2D risk; 
however the role gender has on the clinical manifestation of T2D is still poorly 
understood and varies worldwide(Centers for Disease Control and Prevention, 2011).  
Family history also plays a major role in T2D risk. Having at least one parent with T2D 
increases the risk of developing T2D in 40% of individuals and in 70% of individuals 
with two affected parents, indicative a strong genetic component (Ahlqvist et al., 2011). 
Together, known modifiable and unmodifiable risk factors only account for a 
small portion of T2D cases.  Several investigators have identified unusual cases of obsese 
individuals that never develop T2D, suggestive of a large genetic component explaining 
T2D risk. Concordance rates in monozygotic twins with T2D have been reported to be as 
much as 70% compared to 20-30% in dizygotic twins (Kaprio et al., 1992; Newman et 
al., 1987). And, as previously mentioned, non-European populations have an increased 
prevalence of T2D. After adjusting for traditional T2D risk factors: age, sex, BMI, 
education, and physical activity; Native Americans, African Americans, and Lantinos 
still have increased risk of T2D compared to European Americans (Maskarinec et al., 
2009). These findings give insight to the possibility that differences in genetic ancestry 
could explain increased disease prevalence as even ethnic and gender differences for T2D 
prevalence can be explained by genetic factors (Ahlqvist et al., 2011).  
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While all these studies insinuate a large genetic component involved in the 
etiology of T2D, the role genetic ancestry affects disease risk is poorly understood. 
Common approaches to identify genetic risk factors such as candidate gene studies, 
GWAS, and linkage studies have failed to explain the racial/ethnic disparity of T2D. 
Alternative methods such as admixture mapping, which comprehensively identifies 
differences in genetic ancestry associated with disease risk in admixed populations, are 
needed to identify genetic loci responsible for ancestry-specific risk for T2D. 
 
 
Figure 1.3 Racial and ethnic difference in diagnosed diabetes.  Modified from (Centers 
for Disease Control and Prevention, 2011).  
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Genetics of Type 2 Diabetes 
Candidate Gene and Genetic Linkage Studies 
As of 2011, over 40 genes have been identified with an association with T2D; 
collectively these genes only account for 10% of the heritability (Ahlqvist et al., 2011; 
Herder and Roden, 2011; Köbberling, 1982; Voight et al., 2010). A genetic linkage study 
is a traditional approach used to identify disease causing genes using family data. 
Linkage methods have been very successful at identifying disease loci that are rare, 
monogenic, have high penetrance, and a known mode of inheritance. However, for 
common diseases such as T2D that are likely caused by a combination of several genes 
with smaller effects, interactions between genes and the environment, and have a 
complex mode of inheritance, these traditional methods are less useful.  
Two genes have been identified by linkage studies, TCF7L2 and CAPN10 
(Duggirala et al., 1999; Horikawa et al., 2000; Hanis et al., 1996; Tong et al., 2009; Grant 
et al., 2006; Reynisdottir et al., 2003).  The transcription factor-7-like 2 is part of bipartite 
transcription factor and is encoded by the TCF7L2 gene, located on chromosome 10. 
Several studies have identified single nucleotide polymorphisms (SNPs) in TCF7L2 
associated with increased risk of T2D, impaired insulin secretion, incretin effects and 
enhanced rate of hepatic glucose production (Grant et al., 2006; Lyssenko et al., 2007; 
lyssVoight et al., 2010; Saxena et al., 2007). The other gene identified by linkage studies, 
CAPN10, encodes a cysteine protease and is involved in glucose metabolism  (Horikawa 
et al., 2000). Both genes have been replicated by association studies; however, only 
TCF7L2 has been identified by genome-wide association studies (GWAS).  
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Another traditional approach, the candidate gene study, has identified a number of 
genes associated with T2D. While several genes have been identified by candidate gene 
studies, only six genes have been consistently associated with T2D: PPARG, WFS1, 
KCNJ11, IRS1, HFN1A, and HNF1B. One of the first genes, PPARG encodes a PPAR-γ 
receptor that is a target for insulin-sensitizing drugs (Deeb et al., 1998). Having an extra 
exon in this gene increases insulin sensitivity in 15% of the European population and 
protects against T2D, a finding that has been consistently replicated (Deeb et al., 1998). 
The WFS1 gene encodes a protein, Wolframin, and has been associated with T2D in a 
small family-based association study (Minton et al., 2002). Since, this association has 
been replicated in larger population-based studies as well as meta-analysis (Sandhu et al., 
2007; Franks et al., 2008).  An ATP-sensitive potassium channel is encoded by the 
KCNJ11 gene and regulates membrane potential (Gloyn et al., 2004). This potassium 
channel regulates glucose-dependent insulin secretion in pancreatic beta cells, and 
mutations in this gene lead to T2D (Hani et al., 1998; Gloyn et al., 2003; van Dam et al., 
2005; Saxena et al., 2007; Scott et al., 2007; Zeggini et al., 2007). The gene IRS1 encodes 
a protein insulin receptor that plays an important role in insulin function (Almind et al., 
1993). This association was originally identified in 1993 but failed to replicate for several 
years until recent GWAS.  The genes HNF1A and HNF1B encode transcription factors 
and have been identified by candidate gene studies with an association with several forms 
of maturity onset diabetes of the young (MODY) (Winckler et al., 2007; Holmkvist et al., 
2006; Holmkvist et al., 2008; Voight et al., 2010; Gudmundsson et al., 2007). MODY is 
often referred to as monogenic diabetes and having mutations in one of these genes 
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results in diabetes compared to T2D, which is polygenic  (Goldstein and Müller-Wieland, 
2008). 
Genome-wide Association Studies 
 Unlike candidate gene studies, genome-wide association studies are considered 
hypothesis-free with respect to suspected or known biology.   And, unlike linkage, GWA 
studies are more powerful in identifying common variants with small to moderate genetic 
effects typical of complex diseases such as T2D. As such, GWAS studies have been more 
successful for T2D than both linkage and candidate gene studies combined (Figure 1.4). 
Over 30 novel loci have been identified by GWAS for T2D or related phenotypes (Herder 
and Roden, 2011). These loci are common and have an allele frequency >25% with small 
single SNP effects (average odds ratio (OR) 1.0-1.3). The largest single SNP effect 
reported by GWAS is rs7903146, located in TCF7L2, which as originally identified by 
linkage analysis (Dupuis et al., 2010). Other loci such as KCNJ11 and IRS1 were also 
replicated by GWA studies (Saxena et al., 2007; Scott et al., 2007; Zeggini et al., 2007; 
Rung et al., 2009).  Some of the novel findings identified by GWAS for T2D include 
KCNQ1, CDKN2A/CDKN2B, IGF2BP2, and SLC3OA8 (Saxena et al., 2007; Scott et al., 
2007; Sladek et al., 2007; WTCC, 2007).  
At the time GWAS on T2D were limited to a case-control study design and even 
with the wave of meta-analyses, were subject to limited power. Often for common 
diseases the use of quantitative measurements can improve power to detect an 
association. Quantitative measurements of T2D include fasting glucose, 2-hour glucose 
tolerance test, glycolated hemoglobin A1c (HbA1c), fasting insulin, markers of insulin 
resistance and beta cell function, body mass index, and fat mass. One meta-analysis 
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identified 16 loci associated with fasting glucose that explain about 10% of the trait 
variability for these traits (Dupuis et al., 2010). Only seven loci were actually associated 
with T2D outcome in replication studies (Dupuis et al., 2010). These findings suggest 
that disease loci may contribute to quantitative measurements such as fasting glucose but 
not to T2D, a common limitation to quantitative study designs (Dupuis et al., 2010). The 
FTO gene that encodes the enzyme alpha-ketoglutarate-dependent dioxygenase is 
strongly associated with obesity (Dina et al., 2007; Frayling et al., 2007). This 
association, unlike most associations with quantitative measurements thought to be 
involved in the pathophysiology of T2D, is also associated with T2D in studies not 
matched on BMI (Vimaleswaran and Loos, 2010).  
Beyond GWAS 
 GWAS have identified several loci associated with T2D but these variants are 
common, have small effects, and explain a small portion of the heritability. Thus, other 
approaches besides GWAS are needed to potentially explain the missing heritability 
(Manolio et al., 2009).  One such approach would be to examine rare variants with 
modest to large effects missed by current methods. Rare variants can be missed by 
linkage studies for T2D where a significant amount of genetic heterogeneity exists and by 
GWAS if they are rare in the target population (Ahlqvist et al., 2011). With the 
emergence of high-throughput next generation sequencing and custom genotyping chips, 
the identification of rare disease variants is expected to increase.  
Type 2 diabetes has a large environmental component and is likely caused by 
several genes. Therefore it is highly plausible that gene-gene and gene-environment 
interactions will explain some of the missing heritability for T2D. To date, little is known 
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about the effects these interactions have on T2D. In 2011, Bell et al identified espistatic 
interactions with TCF7L2 and FTO, TSPAN8 and CDKAL1 but these studies were 
underpowered and have yet to be replicated (Bell et al., 2011). There have been few 
studies that identify gene-environment interactions associated with T2D or related 
phenotypes. This is mainly due to the imprecise and unreliable ways to measure 
environmental factors in large populations. Despite these limitations one study has 
identified an association between dietary whole-grain intake and fasting glucose 
(Nettleton et al., 2010).  
 
Figure 1.4 Effect sizes of common variants associated with T2D by candidate gene 
studies and GWAS. Obtained from  (Frayling, 2007) 
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 A portion of the missing heritability could also be explained by expanding 
association studies to more diverse populations. There are several genetic differences 
observed across populations such as differences in allele frequency and linkage 
disequilibrium (LD) patterns (Rosenberg et al., 2010). Linkage disequilibrium is the non-
random association of alleles in the genome. Numerous factors can influence LD patterns 
such as mutations and recombination. Because the human species originated in Africa,   
African-descent populations are more likely to have gone through more recombination 
events and have accumulated more mutations over time compared with European-descent 
populations (Rosenberg et al., 2010; Teo et al., 2010; Teo et al., 2009). Thus, African 
descent populations have more genetic variation and lower spans of LD in the genome 
compared to Europeans.  
Although genetic association studies have been performed in African descent 
populations, most studies are performed in European populations. These studies rely on 
the sometimes extensive LD patterns in European populations to identify single 
nucleotide polymorphisms (SNPs) associated with common diseases or traits. SNPs 
associated with disease are likely tagSNPs rather than the true causal variant.  This 
property of LD in disease mapping is often referred to as a double-edge sword:  the 
extensive LD allows the identification of assoications but makes it difficult to identify the 
true causal variant behind the association.   
One approach to identifying the true causal variant(s) is to use African descent 
populations to fine-map the region where an association has been identified in a 
European population. This is often achieved by densely genotyping a region of interest in 
an African descent population, where more genetic variation exists. Another benefit to 
14 
 
using diverse populations such as African Americans is to assess the extent to which 
results originally identified in European populations can be generalized to other 
populations.   
Admixture Mapping as Tool to Identify Disease Loci 
 Both fine-mapping and generalization in diverse populations rely on previous 
studies to identify regions of interest associated with a disease or trait of interest.  Genetic 
discovery in diverse populations often involves the traditional study designs mentioned 
above such as linkage or GWAS.  More recently, with the advent of cost-effective 
genome-wide genotyping, admixture mapping methodology has become a popular tool in 
the growing arsenal of genetic association discovery methods. 
 Admixture is the result of gene flow over time between genetically distinct human 
populations which leads to a mosaic of chromosomal segments representing each 
population (Figure 1.5).  The gene flow can be a single event or a continual event over 
many generations (Winkler et al., 2010). The proportion of admixture is determined by 
the rate, direction, and duration of gene flow in the population (Winkler et al., 2010).  In 
an admixture event large haplotype blocks from each population are observed in the first 
few generations. Haplotype blocks are in high linkage disequilibrium (LD) and decrease 
in size as generations of admixture increase (Figure 1.5). 
 There are several admixed populations that exist today. Particularly in the United 
States there are two large admixed populations, African Americans and Latinos. African 
Americans were derived from an admixture event dating back to the 16
th
 century during 
the trans-Atlantic slave trade. Today African Americans on average have gametes that are 
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~80% African derived and ~20% European derived (Patterson et al., 2004; Reiner et al., 
2005). American Latino populations are admixed and are the result of a three way 
admixture event between European, African, and Native American ancestry (Bertoni et 
al., 2003; Collins-Schramm et al., 2004; Bonilla et al., 2004; Madrigal et al., 2001). The 
Latino population is larger and much more diverse compared to African Americans and 
the proportions of admixture vary significantly by geographical region (Bertoni et al., 
2003; Collins-Schramm et al., 2004; Bonilla et al., 2004; Madrigal et al., 2001).  
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Figure 1.5. Chromosomal ancestry resulting from 8-20 generations of two-way 
admixture events. Each shade of green represents each ancestral population. Over time 
(each row) recombination produces chromosomal blocks of different ancestries. The 
present day admixed population has blocks of ancestry that vary and size. Obtained from 
(Winkler, 2010 28261 /id). 
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In 1959, Rife proposed the idea that the large blocks linkage disequilibrium 
created by admixture events can be used to assign traits to linkage groups (RIFE, 1954). 
Since the late 1980’s there has been a strong interest in developing statistical methods to 
study this possibility.  One of the first was mapping admixture linkage disequilibrium 
(MALD) (Stephens et al., 1994). This method was based on the association between a 
marker allele and a trait to assign genes to a linkage group (Stephens et al., 1994). 
Recently, more attention has been focused to determine if admixture mapping could also 
be used to identify potential disease loci (Figure 1.6). To do so, alternative methods have 
been developed that test for an association of the disease with parental ancestry. These 
methods are based on local chromosomal ancestry rather than LD like previous methods 
and can be applied to a case/control study design (Price et al., 2009). The application of 
admixture mapping to identify disease loci is based on the hypothesis that disease loci in 
the admixed population will be more frequent in chromosomal segments derived from the 
ancestral population with higher disease prevalence (Winkler et al., 2010). For example, a 
disease such as hypertension, which is more prevalent in African descent populations, 
will have cases with an increased amount of African derived alleles at the disease causing 
locus (Figure 1.5). Current methods are designed for populations derived from two-way 
admixture events and dichotomous disease outcomes. 
 Admixture mapping has successfully identified disease loci in African Americans 
for several common diseases such as end stage renal disease, white blood cell count, and 
prostate cancer(Freedman et al., 2006; Haiman et al., 2007; Kao et al., 2008; Gower et 
al., 2002; Reich et al., 2009). While GWAS have identified over 30 loci for T2D, the 
majority of the studies have been performed in European descent populations and these 
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variants collectively account for a small fraction of the genetic component of the disease. 
Since T2D disproportionately affects admixed populations such as African Americans; 
using admixture mapping to identify potential disease loci is a promising tool to identify 
additional and possibly population-specific variants relevant to T2D risk.   
   
Figure 1.6. Schematic of the pattern of chromosomal admixture around a disease 
locus. Obtained from (Winkler et al., 2010) 
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CHAPTER II 
 
ADMIXTURE MAPPING REVEALS POTENTIAL NOVEL LOCI FOR TYPE 
2 DIABETES IN AFRICAN AMERICANS 
Introduction 
As previously mentioned, T2D disproportionately affects African Americans 
compared to individuals of European descent.  To date there have been several GWAS 
for T2D in Europeans.  To confirm associations identified from these studies we will 
need to assess their role in other populations, especially populations with increased 
prevalence of diabetes, such as South Asian, African American and Mexican American 
populations (Frayling, 2007). In African Americans several genetic association studies of 
T2D related phenotypes such as hypertension, BMI, and fat mass have been performed 
(Adeyemo et al., 2009; Cheng et al., 2009; Helgadottir et al., 2006; Hooper et al., 1999; 
Norris et al., 2005; Plant et al., 2006; Van Norstrand et al., 2008). Genetic association 
studies have not been extensively performed in African Americans for T2D as an 
outcome variable (Haiman et al., 2012). 
Until recently it has been difficult to use identify disease loci in recently admixed 
populations since the methods to study admixture are new and underdeveloped.   
Admixture mapping is an alternative method that detects differences in ancestry in 
admixed individuals and the association these differences may have with the disease. 
Admixed populations, such as African Americans, have mosaic genomes with varying 
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portions derived from either European or African ancestry (Figure 1.5). Admixture 
mapping compares differences in allele frequencies between ancestral populations at each 
locus between cases and controls (Figure 1.6). Performing an admixture scan for diseases 
such as T2D, for which the disease prevalence is twofold higher in African Americans, is 
ideal and will lead to the identification of novel disease loci. This method may also be 
more powerful when compared to traditional approaches that require large sample sizes 
to detect an association. We hypothesize T2D associated loci will have increased African 
ancestry in T2D cases compared to controls.  
A complementary approach to the use of alternative statistical approaches to 
increase power to detect association with disease is the use of alterntive methods for 
ascertainment.  Assessing the use of electronic medical records (EMRs) systems coupled 
to DNA repositories as a resource for genome science is one of the primary objectives for 
the National Human Genome Research Institute’s electronic MEdical Records and 
GEnomics (eMERGE) Network (McCarty et al., 2011). Studies from eMERGE have 
demonstrated that EMR-based genetic association studies replicate existing findings and 
discover novel associations (Denny et al., 2011; Denny et al., 2010; Crosslin et al., 2011; 
Turner et al., 2011). In the present study, we sought to first generalize previous GWAS 
associations and identify novel disease loci for T2D in African Americans. To access 
whether genetic ancestry is associated with T2D risk, we then performed a genome-wide 
admixture scan. 
Methods 
Study Population 
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African American subjects were collected from the Vanderbilt and Northwestern 
University biobanks. The Vanderbilt biobank, BioVU, is a collection of DNA samples 
from discarded blood samples collected for routine clinical care linked to de-identified 
electronic medical records (EMRs) (Roden et al., 2008).  The Northwestern biobank, 
NUgene, combines DNA samples from consented participants with enrollment 
questionnaire and longitudinal data from the EMR (McCarty et al., 2011). Both biobanks 
were approved by Institutional Review Boards at their respective sites.   
Patients with available DNA samples were selected from BioVU and/or NUgene. 
BioVU subjects were African American as indicated by observer reported ancestry, 
which is highly concordant with genetic ancestry (Dumitrescu et al., 2010).   African 
American ancestry was self-reported for Northwestern subjects (McCarty et al., 2011), 
which is also known to be highly concordant with genetic ancestry (Yaeger et al., 2008). 
Our algorithm was carefully designed by expert clinicians experienced with T2D 
diagnosis. T2D cases were defined as having the following in their EMR: a T2D ICD-9 
medical billing code, information about insulin medication, abnormal glucose or HbA1c 
levels, or more than two diagnoses of T2D by a clinican. All T2D cases with an ICD-9 
code for T1D were removed from further analyses. All control subjects had to have at 
least 2 clinical visits, at least one blood glucose measurement, normal blood glucose or 
HbA1c levels, no ICD-9 codes for T2D or any related condition, no history of being on 
insulin or any diabetes related medication, and no family history of T1D or T2D. Using 
these criteria, an automated method selected cases and matched controls and is described 
in Figures 2.1 and 2.2.  Study population demographics and differences between cases 
and controls are described in Table 2.1.  
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Table 2.1. Population Characteristics. We calculated descriptive statistics in African 
American T2D cases and controls separately. We also compared differences between 
cases and controls for these characteristics using either Student’s T-test or Chi2 in 
STATA. 
Variable 
Cases 
(n=736) 
Controls 
(n= 827) 
P-value 
Mean Age (yrs) 53 
 (± 13.41) 
43  
(±14.55) 
<0.00001 
% female 
62% 67% <0.04 
Mean BMI (kg/m
2
) 35 
 (±8.88) 
30  
(±7.61) 
<0.0001 
Mean % European Ancestry 20.3%  
(±11.64) 
20.6%  
(± 14.26) 
0.36 
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Figure 2.1 Flow chart for Type 2 Diabetes case definition. 
 
Figure 2,2 Flow chart for Type 2 Diabetes control definition 
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Genotyping and SNP selection 
All individuals that met the inclusion criteria were genotyped for >1.1 million 
SNPs using the Illumina 1M BeadChip at the Broad Institute. Data were cleaned by the 
eMERGE QC pipeline (Zuvich et al., 2011). Individuals with cryptic relatedness, 
ancestry inconsistent with observer- or self-reported ancestry, anomalous X-chromosome 
heterozygosity or poor genotyping efficiency were removed from further analysis (n = 
46). All markers that were intensity probes, had technical failures, were monomorphic, 
had genotyping efficiencies <99%, had discordant calls with duplicates, had a Hardy 
Weinberg p-value <1 x 10-4, and had >0 Mendelian errors were removed. A total of 
930,000 SNPs remained for association analyses after quality control. 
Statistical Methods 
We first performed a genome wide association study (GWAS) with >900,000 
SNPs genotyped on the Illumina 1M Bead Chip. Assuming an additive genetic model, we 
performed single SNPs tests of association in 736 T2D cases and 827 controls using 
logistic regression in PLINK (Purcell et al., 2007). All tests were adjusted for age, sex, 
and the first three principle components. 
Using our GWAS genotype data we also performed an admixture scan on a subset 
of 4,333 autosomal ancestry informative markers (AIMs) on the Illumina 1M BeadChip 
(Tandon et al., 2011). Using ANCESTRYMAP we tested AIMs for disease risk variants 
that differ in frequency across ancestral populations in our African American study 
population (Patterson et al., 2004). This method uses a Bayesian-likelihood ratio test to 
identify disease associations throughout the genome (Patterson et al., 2004). Genome-
wide ancestry estimates for each individual are averaged across all individuals. A region 
where enhanced ancestry from one ancestral population is observed compared to the 
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average across all individuals is indicative of disease association (Patterson et al., 2004). 
Two statistics are used to determine disease association:  the locus genome statistic (LGS, 
>2.0 significant) and the case-control statistic (CCS, >4.0, significant).  In this study we 
used ANCESTRYMAP to identify average proportion of European ancestry for each 
individual and to identify disease loci throughout the genome.  Pairwise linkage 
disequilibrium (r
2
) was calculated and plotted using Haploview (Barrett et al., 2005). 
Power calculations were performed using Quanto (Gauderman and Morrison, 2006).  
 
Results 
GWAS 
There was only one SNP, rs7903146, that met the genome-wide significance at 
p<10
-8
 (OR=1.7, p=1.17 x 10
-8
) in our African American study population. This intronic 
SNP is located on chromosome 10 in the transcription factor 7 –like 2 (TCF7L2) gene 
and has been previously identified with an association with T2D and related phenotypes.   
There were three novel SNPs that were significant at the p<10
-6
 level (Figure 2.3). 
Intergenic SNP, rs9347819, located on chromosome 6 increases the risk of T2D (OR= 
1.9, p=5.63 x 10
-7
). Intronic PRUNE2 rs11177982 located on chromosome 9 is associated 
with increased risk for T2D (OR = 2.15, p= 7.112 x 10
-6
). One SNP, rs1048317, is 
located intron of LARGE on chromosome 22 and is less frequent in cases compared to 
controls. There were no other SNPs that reached genome-wide significance at p<10
-8
 or 
suggest a possible association at p<10
-6
. 
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Figure 2.3  Genome-wide Association Results for T2D in African Americans from VGER/NUgene. We performed single SNP 
test of association with >930K SNPs across the genome using logistic regression in 736 T2D cases and 827 controls. The red line 
indicates the genome-wide significance level p<10
-8
 and the blue line is indicate of suggestive associations at p<10
-6
.
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Admixture Mapping 
  We performed an admixture scan on a subset of 4,016 ancestry informative 
markers (AIMs) that passed QC and were genotyped on the Illuminia 1M Bead Chip 
using ANCESTRYMAP. Global estimates of European ancestry across the genome were 
calculated for T2D cases and controls. As expected there were no differences in European 
ancestry between cases and controls (p = 0.71). On average cases and controls have 
20.3% and 20.5% their genome of European ancestry (Figure 2.4). 
 In addition to global admixture estimates, we also sought to localize T2D risk 
variants in our African American study population. We tested AIMs across entire genome 
for variants with a higher percentage ancestry from one ancestral population in cases 
compared to controls. The global LGS across the all autosomes was 0.05 indicating most 
loci in the genome were not associated T2D status in this study population (Figure 2.5). 
The lowest LGS (averaged across the entire chromosome) was -0.89, on chromosome 7 
and the highest estimate was on chromosome 11 (Figure 2.5). Chromosome 11 was the 
only region in the genome with a significant LGS (LOD = 2.30).  Variants in this region 
had a local LGS ranging from 2.05 to 2.34 and a CCS ranging from 3.2 to 3.7 (Figure 
2.6). This region spans about 2,800 kb and encompasses over 90 genes (Figure 2.6). One 
SNP, rs308328 had the highest CCS (3.7) and is located in intron of the UNC93B1. This 
gene has no known function in humans; however, it is about 50kb upstream of TCIRG1, 
which is expressed in the pancreas. 
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Figure 2.4 Comparison of global European Ancestry in African American cases of 
T2D and controls. Genome wide estimates of percent European ancestry were calculated 
for each individual using ANCESTRYMAP. Average European ancestry was compared 
between cases and controls (p= 0.72). 
 
0
.2
.4
.6
.8
1
%
 E
u
ro
p
e
a
n
 A
n
ce
sr
ty
0 1
European Ancestry
Controls                  Cases 
29 
 
 
(A) Admixture mapping results chromosome 1-8. 
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(B) Admixture mapping results for chromosomes 9-16.  
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(C)  Admixture mapping results for chromosomes 17-22. 
Figure 2.5 Local estimates of locus genome stastic across the genome for T2D cases and controls.  We performed a genome-wide 
admixture scan in T2D cases and controls. Plotted on the y-axis is the local LGS by the location of each variant on the x-axis. The red 
line indicates the level of signifigance (LGS >2.0) and the circled region is the significant region identified from the admixture scan.
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Figure 2.6. Local admixture results on Chromosome 11.  Regional view of chromosome 11 with significant LGS score of 2.0 or 
greater. Plotted on the y-axis is the local LGS by variant location on the x-axis.  
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Figure 2.7 Genes in the region under the admixture peak on chromomsome 11. Using Seattle SNPs genome browser we 
identified all of the genes located in the significant region on chromosome 11 http://pga.gs.washington.edu/. The TCIRG1 gene 
indicated by the arrow was selected for as a candidate gene to fine-mapping. 
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Discussion 
 We successfully identified several associations with T2D in African Americans 
using samples derived frm a biorepository linked to EMRs. Notably, we were able to 
replicate a known association, rs7903146, in our African American study population. 
Similar to European populations (MAF = 0.29, OR = 1.26)  (Tong et al., 2009), this SNP 
is common in African Americans (MAF = 0.30) and is associated with T2D risk (OR = 
1.69). We were also able to identify potential novel disease genes by admixture mapping 
that can be used for future fine mapping studies. 
 There were three associations identified in our initial GWAS that suggest an 
association with T2D in African Americans (Figure 2.3) Intergenic SNP rs9347819 
increases the risk of T2D and is common African Americans compared to European 
descent populations (HapMap CEU MAF = 0.13 and 0.04, respectively). The nearest 
gene, QKI encodes a RNA binding protein and plays a  role in schizophrenia, but to date 
has never been identified for T2D (Aberg et al., 2006b; Aberg et al., 2006a; Lindholm et 
al., 2001). The other SNPs rs11177982 (PRUNE2) and rs1048317 (LARGE) also have 
never been reported to have an association with T2D. As opposed to mutations, the 
effects of common variation are less clear. All of the SNPs identified in this GWAS are 
located in the intronic regions with no obvious biological relevance.  This region also has 
low LD in African Americans and associated SNPs are not correlated with presumed 
functional variants.  Despite this finding, reporting these results is still important as 
intronic SNPs such as rs7903146 (TCF7L2) have functional relevance to T2D (Grant et 
al., 2006; Lyssenko et al., 2007; Tong et al., 2009). 
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 Using admixture mapping we were able to detect a significant admixture peak on 
chromosome 11. The region under the peak was large and included over 90 genes (Figure 
2.7).  Our most significant finding rs308328 is located in the UNC93B1 gene. This gene 
encodes the 12 membrane spanning protein UNC-93B and is involved in the exogenous 
antigen presentation and the signaling of toll-like receptors (Tabeta et al., 2006).  
Mutations in UNC93B1 in humans have led to impaired production of interferon which is 
necessary to fight herpetic virus infection (Casrouge et al., 2006). To our knowledge this 
gene has no direct correlation with T2D, however UNC93B1 is located upstream of 
TCIRG1 which is highly expressed in the pancreas. While this region is gene rich, there 
are only 146 common SNPs reported in Yoruban (YRI) HapMap samples within 100kb 
of the UNC93B1 gene (The International HapMap Project, 2003). To determine if 
rs308328 is correlated with SNPs in the TCIRG1 gene and thus representing this effect 
we calculated pairwise LD (r
2
) in this region (Figure 2.8).  There were only 59 SNPs in 
this region genotyped in our study population, and there were high levels of linkage 
disequilibrium in our African Americans study population (Figure 2.8).  However there is 
only one SNP rs308351, located in an intergenic region, which is in moderate LD with 
rs308328 in our data.  Further fine-mapping and/or deep re-sequencing will be required to 
uncover the functional variant in this region in African-descent populations. 
There were several limitations to the present study. Particularly, for our GWAS 
we were underpowered to detect effects smaller than 1.6 (OR) for SNPs with common 
SNPs (MAF >0.05).   Our study population compared to recently published GWAS for 
T2D is relatively small and underpowered. Also, most GWAS fixed-content products are 
biased to common variation and based on LD patterns observed in European populations 
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(Spencer et al., 2009). Therefore, the SNPs on these platforms capture the majority of 
common variation in Europeans but perform worse in African-descent populations.  Also 
rare variation and/or population-specific variation are underrepresented in GWAS fixed-
content products.  These limitations impact our power to detect associations for T2D in 
diverse populations.   
Further limitations include the fact that this admixture scan was limited to 
ancestry informative markers (AIMs) genotyped on the Illumina 1M.  A total of 4,016 
AIMs were used, which only represents 0.37% of the markers genotyped in the entire 
dataset. The AIMs  were previously identified for several GWAS platforms by Tandon et 
al (Tandon et al., 2011). It is possible that are several SNPs genotyped on these platforms 
that do not meet the criteria outlined by Tandon et al but are informative and possibly 
associated with T2D status (Tandon et al., 2011). Additionally, we only included SNPs 
that were unlinked (r
2
< 0.80), a requirement of the ANCESTRYMAP software package 
(Patterson et al., 2004). Other methods have recently been developed that can 
accomodate correlated SNPs, which increase power and give better estimates of local 
ancestry estimates in the genome (Price et al., 2009).  
 We used a case-control study design for both the GWAS and the admixture scan. 
However, using quantitative traits is an excellent alternative to using clinical outcomes 
for complex diseases. Quantitative measurements can be more robust to phenotypic 
heterogeneity and are often more uniform compared to disease outcomes. Given the 
complexity of T2D, it is likely that different genetic etiologies explain several traits or 
intermediate phenotypes associated with T2D. Quantitative measurements such as BMI 
and fat mass have been used to identify genetic risk factors of T2D. One example is with 
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SNPs in the FTO gene and obesity; an association that has been well-characterized (Dina 
et al., 2007; Frayling et al., 2007; Scuteri et al., 2007). We were unable to reproduce this 
finding using a case-control study design in our analysis, which is likely a result of power 
(p-value > 0.40) (Figure 2.3).  
Alternatively, one would argue that using a disease outcome is more informative 
compared to quantitative measurements, given the direct and obvious correlation to the 
disease. One major limitation to using intermediate phenotypes (such as quantitative 
measurements) is the assumption that the associations identified are also associated with 
the disease. We successfully identified several novel associations across the genome 
using T2D disease outcome status in our GWAS (at the p<10
-6
 level) and genome-wide 
admixture scan.  Our admixture scan revealed a region on chromosome 11 that might be 
associated with T2D. These data suggest that the functional variants have yet to be 
identified for T2D and emphasize the need for future fine mapping studies in a larger 
African-descent population. Subsequent fine-mapping studies will provide a better 
understanding these associations with T2D. 
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Figure 2.8. Linkage disequilibrium around the 100kb around rs308328 in African American T2D cases and controls. We  
calculated pairwise LD around our most significant finding (circled in red) from the admixture scan in our AfricanAmerican study 
population using Haploview (Barrett et al., 2005). 
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CHAPTER III 
 
FINEMAPPING THE TCIRG1 REGION IN AFRICAN AMERICANS 
Introduction 
In Chapter II we identified a potential disease region on chromosome 11 that 
includes over 90 genes (Figure 2.7). Our most significant association, rs308328, is 
located in UNC93B1 which has no direct biological relevance to T2D. Further 
investigation of this region revealed a potential candidate gene, TCIRG1, which is 
expressed in the pancreas; a vital organ involved in the pathogenesis of T2D. Our initial 
analysis was limited to AIMs and warrants fine mapping studies to elucidate the role this 
region has with T2D.  
Fine-mapping is a complementary approach to gene discovery methods such as 
GWAS and admixture mapping to identify potential ‘causal’ variants among highly 
correlated SNPs. This method requires densely genotyping or sequencing the region of 
interest.  Fine-mapping studies are usually hypothesis-driven where a gene is selected 
within the associated region that is suspected to be biologically relevant to the phenotype 
being studied. For example, this approach would be useful to follow-up the UNC93B1 
region, where the SNP rs308328 is associated with T2D, but has no obvious biological 
relevance to T2D. Performing fine-mapping studies in this region using a large sample of 
African Americans may help identify the putative casual variants in UNC93B1 and other 
genes identified by GWAS with unknown biological function. Therefore, using additional 
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African Americans in BioVU we sought to fine-map the UNC93B1 gene region in T2D 
cases and controls. 
 
Methods 
Study Population 
All subjects were observer-reported African American, at least 18 years of age, 
and were collected from the Vanderbilt University biobank, BioVU (see Chapter II, page 
20). The algorithms used to define cases and controls have been previously described in 
Chapter II, figures 2.2 and 2.2. Since BioVU accrues new samples each week, we re-ran 
the algorithm for this follow-up study in June of 2011 (~a year later). We identified a 
total of 1,659 cases and 3,372 controls for this fine-mapping study, of which 1,272 
samples overlap with the discovery study described in Chapter II. Study population 
characteristics are described in Table 3.1. 
 SNP Selection and Genotyping 
We genotyped 51 tagSNPs approximately 100kb upstream and downstream of the 
TCIRG1 gene, previously identified by admixture mapping (see Chapter II, figure 3.1). 
HapMap Yoruban population linkage disequilibrium patterns were used to select tagSNPs 
in this region (Figure 3.1 http://pga.gs.washington.edu/ ).  All tagSNPs with a minor 
allele frequency >0.08 were selected for this analysis. For quality control purposes, we 
purposely included 20 (out of 1276) SNP pairs that are in high linkage disequilibrium 
(LD) (r
2
>0.80) with each other. Genotyping was performed at the Vanderbilt University 
Center for Human Genetics Research DNA Resources Core. The quality control metrics 
described in Chapter II were also used for this analysis. 
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Statistical Methods 
Using logistic regression, we performed single SNP tests of association assuming 
an additive genetic model for SNPs that passed QC in PLINK (Purcell et al., 2007).  
Analyses were performed unadjusted and adjusted for age and sex. All results were 
plotted using Synthesis-View (Pendergrass et al., 2010).  To account for multiple testing, 
we employed Bonferonni correction and declared a significance threshold of p<0.001. 
Linkage disequilibrium was calculated by measuring the correlation coefficient r
2
 in 
Haploview (Barrett et al., 2005).  
Results 
 We detected several novel associations near the candidate region identified by 
admixture mapping in Chapter II. There were seven SNPs that met our conservative 
Bonferroni significance threshold of p<0.001, all of which are located in the CHKA gene.  
Having one or more copies of the minor allele increases the risk of having T2D in 
African Americans for six of these SNPs (OR= 1.08- 1.37). One SNP rs10791957 has a 
protective effect decreasing the risk of T2D (OR= 0.83). There were an additional twelve 
SNPs within this region that were significant at the p<0.05 level, suggestive of an 
association. There were seven SNPs in the CHKA gene, three SNPs in the ALDH3B1, and 
two SNPs in the TCIRG1 that trended towards significance (Table 3.2). Of the twelve 
associations having one or more copies of the minor allele decreseases the risk of T2D 
for half (six SNPs) while the other half increases the risk of T2D in African Americans 
(Table 3.2). 
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 As previously mentioned, we selected several SNPs in high LD for quality 
control purposes.  To distinguish between independent and redundant results, we 
calculated pairwise LD between all SNPs in our African American study population 
(Figure 3.2). There were a total of 22 highly correlated SNP-SNP pairs (r
2
>0.80), 20 of 
which were expected based on our assay design (Figure 3.2).  Taking into account these 
correlations, there were only three independent associations (r
2
< 0.80) that met our 
significance threshold. However even these associations are in moderate LD (r
2
 <0.80 
and >0.40). 
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Table 3.1. Study population demographics for 4,246 unrelated African Americans in 
BioVU.  We calculated descriptive statistics and tested whether there were differences 
between cases and controls for these characteristics in using either Student’s T-test or 
Chi
2
 in STATA. 
 
 
 
 
Figure 3.1 Candidate region targeted for fine mapping. Using Seattle SNPs genome 
browser the candidate genes located within 100kb of the TCIRG1 gene, their orientation, and 
gene structure are displayed.  SNPs annotated for these genes are located at the top of the 
figure denoted by hash marks.  (Image generated from http://pga.gs.washington.edu/).
Variable 
Cases 
(n= 1,602) 
Controls 
(n=2,644) 
P-value 
Mean Age (yrs) 
52 
(±15.83) 
46 
(±18.84) 
<0.00001 
Sex (% female) 67% 67% 0.23 
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Table 3.2. Fine mapping association results. We performed logistic regression with 48 SNPs within 
100kb of TCIRG1 gene with T2D case/control status in 4,246 African Americans. All tests were adjusted 
for age and sex, assuming an additive model. Bolded are significant results p-value < 1.0 E
-3
. 
SNP Gene/ location Coded Allele OR 95% CI SE P 
rs105147 ALDH3B1 intron A 0.89 (0.80, 1.00) 0.06 0.050 
rs2286164 ALDH3B1 intron C 1.09 (0.98, 1.22) 0.05 0.100 
rs2286169 ALDH3B1 intron G 1.15 (1.03, 1.29) 0.06 0.014 
rs308335 ALDH3B1 intron G 0.95 (0.82, 1.09) 0.07 0.455 
rs308337 ALDH3B1 intron A 0.94 (0.81, 1.09) 0.07 0.404 
rs308338 ALDH3B1 intron G 0.93 (0.84, 1.04) 0.05 0.204 
rs557098 ALDH3B1 intron G 0.96 (0.83, 1.10) 0.07 0.562 
rs2286163 ALDH3B1 Ser Ser A 1.16 (1.03, 1.31) 0.06 0.013 
rs11825872 ALDH3B1downstream C 0.90 (0.73, 1.10) 0.10 0.302 
rs3751082 ALDH3B1LeuLeu T 1.07 (0.93, 1.23) 0.07 0.315 
rs12418774 ALDH3B1upstream G 1.16 (0.89, 1.51) 0.14 0.280 
rs3763942 ALDH3B1upstream C 1.00 (0.83, 1.19) 0.09 0.976 
rs7928739 CHKA  intron A 0.87 (0.78, 0.97) 0.06 0.011 
rs3794186 CHKA 3’ UTR T 1.05 (0.87, 1.26) 0.09 0.636 
rs11228145 CHKA downstream T 0.87 (0.76, 1.00) 0.07 0.052 
rs1547888 CHKA downstream C 1.17 (1.03, 1.32) 0.06 0.016 
rs1547889 CHKA downstream T 1.14 (0.99, 1.30) 0.07 0.062 
rs2511469 CHKA downstream A 1.21 (1.09, 1.34) 0.05 4.46E-04 
rs2511470 CHKA downstream C 1.14 (1.01, 1.27) 0.06 0.029 
rs2511472 CHKA downstream C 0.87 (0.78, 0.97) 0.06 0.010 
rs2512623 CHKA downstream T 0.86 (0.77, 0.95) 0.06 0.005 
rs7944372 CHKA downstream C 1.23 (1.11, 1.37) 0.05 1.04E-04 
rs10791957 CHKA intron A 0.83 (0.74, 0.92) 0.05 4.71E-04 
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rs2511437 CHKA intron G 1.20 (1.08, 1.33) 0.05 5.52E-04 
rs2511439 CHKA intron T 1.12 (0.96, 1.31) 0.08 0.159 
rs2512612 CHKA intron C 1.22 (1.10, 1.36) 0.05 1.61E-04 
rs4930557 CHKA intron C 1.22 (1.10, 1.35) 0.05 2.18E-04 
rs6591331 CHKA intron A 1.15 (1.03, 1.28) 0.06 0.016 
rs6591333 CHKA intron G 1.20 (1.08, 1.34) 0.05 8.88E-04 
rs7123035 CHKA intron A 0.97 (0.82, 1.15) 0.08 0.739 
rs7952122 intergenic (UNC93B1 ALDH3B1) A 1.04 (0.93, 1.16) 0.06 0.497 
rs308351 LOC100132261 downstream C 1.05 (0.92, 1.20) 0.07 0.436 
rs308309 LOC100132261 upstream G 0.93 (0.79, 1.09) 0.08 0.362 
rs4147776 NDUFS8  5’ UTR C 1.18 (0.88, 1.58) 0.15 0.277 
rs11824781 NDUFS8 intron C 0.97 (0.84, 1.12) 0.07 0.676 
rs3115545 NDUFS8 intron T 0.94 (0.77, 1.14) 0.10 0.532 
rs10896288 NDUFS8 upstream G 0.95 (0.82, 1.09) 0.07 0.448 
rs11823975 NDUFS8 upstream C 0.88 (0.73, 1.05) 0.09 0.165 
rs3115546 NDUFS8intron G 0.94 (0.83, 1.06) 0.06 0.332 
rs7949541 NDUFS8intron T 1.01 (0.80, 1.28) 0.12 0.931 
rs3133269 NDUFS8upstream C 1.01 (0.90, 1.13) 0.06 0.821 
rs7951010 TCIRG1  upstream T 0.93 (0.76, 1.14) 0.10 0.479 
rs884826 TCIRG1  upstream A 0.87 (0.78, 0.97) 0.06 0.015 
rs2075609 TCIRG1 intron G 1.16 (1.05, 1.29) 0.05 0.004 
rs2240387 UNC93B1 G 1.05 (0.86, 1.13) 0.06 0.380 
rs3808969 UNC93B1downstream C 1.03 (0.87, 1.22) 0.09 0.757 
rs308328 UNC93B1intron A 0.98 (0.86, 1.13) 0.07 0.796 
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Figure 3.2. Linkage disequilibrium around the 100kb around rs308328 in African Americans T2D cases and controls. We  
calculated pairwise LD around our most significant finding (circled in red) from the admixture scan in our AfricanAmerican study 
population using Haploview (Barrett et al., 2005). 
47 
 
 
 
Figure 3.3. TCIRG1 mRNA is highly expressed in human pancreas tissue. Using 
GeneNote (http://bioinfo2.weizmann.ac.il/cgi-bin/genenote/home_page.pl), we identified 
the mRNA expression levels in various human tissues for TCIRG1. 
 
Discussion 
 A review article published in 2007 reported that the next steps (after GWAS) for 
finding diabetes susceptibility loci was to first fine-map the novel T2D loci (Frayling et 
al., 2007). Based on the results from the genome-wide admixture scan performed in 
Chapter II, we sought to fine-map associations with T2D on chromosome 11 in a large 
study population of African Americans. This region included five genes; one of which 
TCIRG1 is highly expressed in the pancreas and yet to be assoicated with T2D. We 
observed a total of seven significant associations in this region at p<0.001, two were in 
TCIRG1 at the p<0.05 level.   
In Chapter II rs308328 was our most significant finding, and the region under the 
>2,500 kb admixture peak included over 90 genes. A 100 kb window surrounding 
TCIRG1 was chosen for fine-mapping based on the possible biological relevance of this 
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gene with T2D. The T-cell immune regulator, ATPase, H+ transporting, lysosomal V0 
subnit A3 gene, TCIRG1, is highly expressed in white blood cells (lymphocytes and 
monocytes) but is also expressed in the adrenal cortex and the pancreas in normal human 
cells (Figure 3.3.). There have been reports of an association with the innate immune 
system and T2D but the exact pathway is still unclear (Pickup, 2004). The pancreas is an 
organ in the endocrine system that produces several hormones including insulin and is 
directly involved in insulin regulation and thus T2D risk.  
We were able to identify several associations in this region; however, there were 
no significant findings in the TCIRG1 gene met our significance threshold (Table 3.2). In 
fact all of the significant associations are located in the choline kinase alpha (CHKA) 
gene, which encodes a protein essential in the phospholipid biosynthesis and may 
contribute to tumor cell growth (Gallego-Ortega et al., 2009; Ramirez de et al., 2008). To 
our knowledge, we are the first to report this association with T2D diabetes. 
This work emphasizes the importance of genetic association studies in African 
American populations. Compared to our discovery analysis in Chapter II, which was 
powered to detect moderate to large associations (≥1.7 OR), the fine-mapping study was 
sufficiently powered (>80%) to detect effects as small as 1.3 (OR) given our sample size. 
Furthermore, fine mapping the TCIRG1 improved our power to directly detect an 
association in this candidate region (Table 3.3.). Of the 51 SNPs selected for fine 
mapping only 29 were directly assayed and genotyped in the original GWAS reported in 
Chapter II.  We identified eight independent associations at p<0.05, five were also 
included in the GWAS. None of these SNPs were significant in our GWAS (p<0.05) 
which might be due to an increase in power (larger sample size) but also indicating that 
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admixture mapping followed by fine mapping is a powerful method in the identification 
of novel disease loci. 
The major limitation of this study is process by which SNPs were selected. First, 
we limited the fine mapping study to one gene region from approximately 90 genes 
located within the admixture peak.  We based our gene selection on known biological 
function and presumed relevance to T2D, but it is possible that other genes within the 
admixture peak are responsible for the association with T2D.  Second, we implemented a 
tagSNP approach to select specific SNPs for genotyping.  The use of tagSNPs is a cost 
effective alternative to genotyping all known common variants regardless of linkage 
disequilibrium patterns throughout the genome. The caveat is that there is a possibility 
that the associated SNPs are not the functional or true “risk” SNP but are in linkage 
disequilibrium with the un-genotyped functional variant. Also, a fraction of SNPs must 
be assayed directly as no SNPs will serve as sufficient tags or proxies.  We selected 
common tagSNPs with a minor allele frequency of at least 0.08 within 100kb of the 
TCIRG1 gene (Figure 3.1).  Selected SNPs had to have an r
2
>0.80 with other SNPs in the 
region to be selected for this analysis. Limiting our analysis to only common tagSNPs we 
fail to capture rare variants which may have large effects on T2D risk. Additionally our 
high r
2
 threshold resulted in several redundant associations due to moderate to high LD in 
this gene region (Table 3.3, Figure 2.8).  Finally, it is possible that we failed to assay a 
sufficient proxy or tagSNP for the true “causal” variant associated with T2D. 
Although we were unable to detect significant associations in the TCIRG1 gene at 
p<0.001, we detected associations with the CHKA gene. We were also able increase our 
power to detect SNPs with small effects in this region by increasing our sample size and 
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fine mapping this gene region. The variants we identified are likely tagSNPs as they have 
no obvious biological function; therefore deep sequencing of this region is warranted to 
identify rare variants and the affect they may have on T2D disease risk.  Overall, these 
data contribute to the understanding of the genetic etiology of T2D in African Americans 
and serve as a starting point for future sequencing and molecular studies to better 
understand the biological processes that lead to T2D and other complex human diseases. 
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